Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIR Trial: Involved-field radiotherapy plus Rituximab for limited-stage follicular lymphoma
2006-001212-72Phase 2Completed
- Sponsor
- Heidelberg University Hospital
- Start
- May 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL), sponsored by Heidelberg University Hospital. Primary endpoint: progression-free survival at 2 years. Started May 2007; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2006-001212-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001212-72.